The above studies had showed that RNF6 was highly expressed in breast cancer tissues and was associated with patient survival, to further measure the effects of RNF6 in primary patients, 136 breast cancer tissues were applied for clinical evaluation in terms of patients' age, clinical stage, the expression of RNF6, ERα, PR and HER2, because the trio of ERα, PR and HER2 are proposed indicators for the prognosis of breast cancer patients. Here, RNF6 is linked to breast carcinoma.